Vimarsana
Biggest News Aggregation in the World

Page 16 - Bgne News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bgne. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bgne Today - Breaking & Trending Today

LVW Advisors LLC Sells 193 Shares of BeiGene, Ltd. (NASDAQ:BGNE) - Vimarsana News

LVW Advisors LLC Sells 193 Shares of BeiGene, Ltd. (NASDAQ:BGNE)

LVW Advisors LLC lowered its stake in BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) by 9.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,799 shares of the company’s stock after selling 193 shares during the period. LVW Advisors LLC’s holdings in BeiGene were worth $487,000 […]

BeiGene (NASDAQ:BGNE) Downgraded by SVB Leerink to "Market Perform" - Vimarsana News

BeiGene (NASDAQ:BGNE) Downgraded by SVB Leerink to "Market Perform"

BeiGene (NASDAQ:BGNE – Get Rating) was downgraded by research analysts at SVB Leerink from an “outperform” rating to a “market perform” rating in a research report issued on Thursday, Briefing.com reports. They currently have a $177.00 price target on the stock, down from their previous price target of $300.00. SVB Leerink’s price target points to […]

BeiGene (NASDAQ:BGNE) Shares Gap Down to $184.00 - Vimarsana News

BeiGene (NASDAQ:BGNE) Shares Gap Down to $184.00

BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) gapped down before the market opened on Friday . The stock had previously closed at $184.00, but opened at $177.01. BeiGene shares last traded at $177.20, with a volume of 1,257 shares. BGNE has been the topic of a number of recent research reports. Deutsche Bank Aktiengesellschaft initiated coverage […]

BGNE Teams Up With Novartis, Editas Slumps Over 15%, Eli Lilly's Drug Shines In TRAILBLAZER-ALZ, Mesoblast On Watch - Vimarsana News

BGNE Teams Up With Novartis, Editas Slumps Over 15%, Eli Lilly's Drug Shines In TRAILBLAZER-ALZ, Mesoblast On Watch

(2) BASEL (dpa-AFX) - Today's Daily Dose brings you news about Lilly's Alzheimer's disease trial data, BeiGene's collaboration agreement with Novartis, Mesoblast's encouraging results from phase III trial of Rexlemestrocel-L in patients with chronic heart failure, and the resignation of Editas' Chief Scientific Officer. Read on. 1. Arcus to Present at ASCO-GI Symposium Arcus Biosciences Inc. (RCUS) said that the dose-escalation portion of its phase I/Ib study evaluating the safety and tolerability of AB680 in combination with Zimberelimab and nab-paclitaxel plus gemcitabine (chemotherapy) in ...

Twitter, Tesla, Realty Income, Cantel Medical: What to Watch When the Stock Market Opens Today - Vimarsana News

Twitter, Tesla, Realty Income, Cantel Medical: What to Watch When the Stock Market Opens Today

Here’s what we’re watching as markets kick into gear on Tuesday. — U.S. stock futures edged higher Tuesday, suggesting major indexes will resume their recent climb after a slide in technology shares weighed on markets at the start of the week. Read our full market wrap here. What’s Coming Up —Home builder KB Home will deliver its quarterly earnings report after markets close. —Live Q&A: Join WSJ chief economics correspondent Nick Timiraos for an interview with the St. Louis Fed’s James Bullard. Bullard at 1 p.m. ET. —The U.S. job openings and labor turnover survey for Novemb...

Source: wsj.com